Mooij W. T. M. et al. “Automated Protein–Ligand Crystallography for Structure-Based Drug Design.” ChemMedChem 1, no. 8 2006: 827–838. DOI: 10.1002/cmdc.200600074.

/in ,

Mooij W. T. M. et al. “Automated Protein–Ligand Crystallography for Structure-Based Drug Design.” ChemMedChem 1, no. 8 2006: 827–838. DOI: 10.1002/cmdc.200600074.

Murray C. W., Verdonk et al. “Entropic consequences of linking ligands.” Fragment-based approaches in drug discovery: Volume 34, Chapter 3, pp 55-66. Edited by W Jahnke and D. A. Erlanson. WILEY-VCG Verlag GmbH & Co. KGaA, Weinheim 2006. ISBN: 978-3-527-31291-7.

/in ,

Murray C. W., Verdonk et al. “Entropic consequences of linking ligands.” Fragment-based approaches in drug discovery: Volume 34, Chapter 3, pp 55-66. Edited by W Jahnke and D. A. Erlanson. WILEY-VCG Verlag GmbH & Co. KGaA, Weinheim 2006. ISBN: 978-3-527-31291-7.

Gill, A., et al. “The Discovery of Novel Protein Kinase Inhibitors by Using Fragment-Based High-Throughput X-ray Crystallography.” ChemBioChem 6, no. 3 2005: 506–512. DOI: 10.1002/cbic.200400188.

/in ,

Gill, A., et al. “The Discovery of Novel Protein Kinase Inhibitors by Using Fragment-Based High-Throughput X-ray Crystallography.” ChemBioChem 6, no. 3 2005: 506–512. DOI: 10.1002/cbic.200400188.

Gill, A.L., et al. “Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation.” Journal of Medicinal Chemistry 48, no. 2 2005: 414–426. DOI: 10.1021/jm049575n.

/in ,

Gill, A.L., et al. “Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation.” Journal of Medicinal Chemistry 48, no. 2 2005: 414–426. DOI: 10.1021/jm049575n.

Hartshorn, M.J., et al. “Fragment-Based Lead Discovery Using X-ray Crystallography.” Journal of Medicinal Chemistry 48, no. 2 2005: 403–413. DOI: 10.1021/jm0495778.

/in ,

Hartshorn, M.J., et al. “Fragment-Based Lead Discovery Using X-ray Crystallography.” Journal of Medicinal Chemistry 48, no. 2 2005: 403–413. DOI: 10.1021/jm0495778.

Kirton, S.B., et al. “Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins.” Proteins: Structure, Function, and Bioinformatics 58, no. 4 2005: 836–844. DOI: 10.1002/prot.20389.

/in ,

Kirton, S.B., et al. “Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins.” Proteins: Structure, Function, and Bioinformatics 58, no. 4 2005: 836–844. DOI: 10.1002/prot.20389.

Miles Congreve, Christopher W. Murray and Tom L. Blundell. “Keynote review: Structural biology and drug discovery.” Drug Discovery Today 10, no. 13 2005: 895–907. DOI: 10.1016/S1359-6446(05)03484-7.

/in ,

Miles Congreve, Christopher W. Murray and Tom L. Blundell. “Keynote review: Structural biology and drug discovery.” Drug Discovery Today 10, no. 13 2005: 895–907. DOI: 10.1016/S1359-6446(05)03484-7.

Robin A.E. Carr, Miles Congreve, Christopher W. Murray, David C. Rees. “Fragment-based lead discovery: leads by design.” Drug Discovery Today 10, no. 14 2005: 987–992. DOI: 10.1016/S1359-6446(05)03511-7.

/in ,

Robin A.E. Carr, Miles Congreve, Christopher W. Murray, David C. Rees. “Fragment-based lead discovery: leads by design.” Drug Discovery Today 10, no. 14 2005: 987–992. DOI: 10.1016/S1359-6446(05)03511-7.

Thompson N., Lyons J. “Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.” Current Opinion in Pharmacology 5, no. 4 2005: 350–356. DOI: 10.1016/j.coph.2005.04.007.

/in ,

Thompson N., Lyons J. “Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.” Current Opinion in Pharmacology 5, no. 4 2005: 350–356. DOI: 10.1016/j.coph.2005.04.007.

Gill, A. L. “New Lead Generation Strategies for Protein Kinase Inhibitors – Fragment Based Screening Approaches.” Mini-Reviews in Medicinal Chemistry 4, no. 3 2004: 301-311.

/in ,

Gill, A. L. “New Lead Generation Strategies for Protein Kinase Inhibitors – Fragment Based Screening Approaches.” Mini-Reviews in Medicinal Chemistry 4, no. 3 2004: 301-311.